VINC vs. MIST, SLS, MRNS, CUE, HOOK, PYRGF, BRNS, DERM, ANIX, and SPRO
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Milestone Pharmaceuticals (MIST), SELLAS Life Sciences Group (SLS), Marinus Pharmaceuticals (MRNS), Cue Biopharma (CUE), Hookipa Pharma (HOOK), PyroGenesis Canada (PYRGF), Barinthus Biotherapeutics (BRNS), Journey Medical (DERM), Anixa Biosciences (ANIX), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical preparations" industry.
Milestone Pharmaceuticals (NASDAQ:MIST) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, community ranking, media sentiment and institutional ownership.
Milestone Pharmaceuticals has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500.
Vincerx Pharma has lower revenue, but higher earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.
86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 10.4% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 22.9% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Milestone Pharmaceuticals had 4 more articles in the media than Vincerx Pharma. MarketBeat recorded 7 mentions for Milestone Pharmaceuticals and 3 mentions for Vincerx Pharma. Milestone Pharmaceuticals' average media sentiment score of 0.96 beat Vincerx Pharma's score of 0.48 indicating that Vincerx Pharma is being referred to more favorably in the news media.
Vincerx Pharma's return on equity of -175.44% beat Milestone Pharmaceuticals' return on equity.
Milestone Pharmaceuticals received 57 more outperform votes than Vincerx Pharma when rated by MarketBeat users. Likewise, 68.14% of users gave Milestone Pharmaceuticals an outperform vote while only 64.52% of users gave Vincerx Pharma an outperform vote.
Milestone Pharmaceuticals presently has a consensus price target of $10.75, suggesting a potential upside of 616.67%. Vincerx Pharma has a consensus price target of $5.00, suggesting a potential upside of 692.39%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vincerx Pharma is more favorable than Milestone Pharmaceuticals.
Summary
Milestone Pharmaceuticals beats Vincerx Pharma on 10 of the 16 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
